PB2056: PREVALENCE OF CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS IN STABLE C5 INHIBITOR-TREATED PATIENTS WITH PNH AND ITS ASSOCIATION WITH DISEASE CONTROL, QUALITY OF LIFE AND TREATMENT SATISFACTION

• Austin Kulasekararaj,
• Jennifer Mellor,
• Lucy Earl,
• Alice Wang,
• Yogesh Patel,
• Karl-Johan Myren,
• Wolfgang Fuereder,
• Srikanth Nagalla

Affiliations

Austin Kulasekararaj

1 Kings College Hospital, National Institute of Health Research/Wellcome King’s College London

Jennifer Mellor

2 Adelphi Real Word, Bollington, United Kingdom

Lucy Earl

2 Adelphi Real Word, Bollington, United Kingdom

Alice Wang

3 Alexion, AstraZeneca Rare Disease, United States

Yogesh Patel

3 Alexion, AstraZeneca Rare Disease, United States

Karl-Johan Myren

3 Alexion, AstraZeneca Rare Disease, United States

Wolfgang Fuereder

4 Division of Hematology and Hemostaseology, Medical University of Vienna, Department of Internal Medicine, Austria

Srikanth Nagalla

5 Miami Cancer Institute, Benign Hematology